-
1.发明授权Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 有权为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2161336B2
公开(公告)日：2017-03-29
申请号：EP09013687.0
申请日：2006-05-02
发明人： Korman, Alan, J. , Srinivasan, Mohan , Wang, Changyu , Selby, Mark. J. , Chen, Bing , Cardarelli, Josephine M. , Huang, Haichun
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：EP2439273B1
公开(公告)日：2019-02-27
申请号：EP11178191.0
申请日：2006-05-02
-
3.发明公开HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) 审中-公开HUMANE MONOKLONALEANTIKÖRPERGEGEN DEN编程死亡1号（PD-L1）
公开(公告)号：EP2982379A1
公开(公告)日：2016-02-10
申请号：EP15172571.0
申请日：2006-06-30
发明人： Korman, Alan J. , Selby, Mark J. , Wang, Changyu , Srinivasan, Mohan , Passmore, David, B. , Huang, Haichun , Chen, Haibin
IPC分类号： A61K39/00 , A61K39/395 , C07K16/28
CPC分类号： C07K16/2827 , A61K45/06 , A61K47/6817 , A61K47/6825 , A61K47/6849 , A61K2039/505 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K2317/21 , C07K2317/41 , C07K2317/56 , C07K2317/567 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.
摘要翻译： 本公开提供分离的单克隆抗体，特别是以高亲和力特异性结合PD-L1的人单克隆抗体。 还提供了编码本公开的抗体的核酸分子，表达载体，宿主细胞和用于表达本公开的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本公开还提供了用于检测PD-L1的方法，以及使用抗-PD-L1抗体治疗各种疾病（包括癌症和感染性疾病）的方法。
-
公开(公告)号：EP2383295B1
公开(公告)日：2015-03-11
申请号：EP11166104.7
申请日：2004-12-10
发明人： Deshpande, Shrikant , Huang, Haichun , Srinivasan, Mohan , Cardarelli, Josephine M. , Wang, Changyu , Passmore, David , Rangan, Vangipuram S. , Lane, Thomas E. , Keirstead, Hans S. , Liu, Michael T.
CPC分类号： C07K16/24 , A61K2039/505 , C07K14/522 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
公开(公告)号：EP2662390B1
公开(公告)日：2017-08-02
申请号：EP13162333.2
申请日：2005-06-20
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92
-
公开(公告)号：EP2865687A1
公开(公告)日：2015-04-29
申请号：EP14191352.5
申请日：2004-12-10
发明人： Deshpande, Shrikant , Huang, Haichun , Srinivasan, Mohan , Cardarelli, Josephine M , Wang, Changyu , Passmore, David , Rangan, Vangipuram S , Lane, Thomas E , Keirstead, Hans S , Liu, Michael T
CPC分类号： C07K16/24 , A61K2039/505 , C07K14/522 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
摘要翻译： 本发明提供以高亲和力结合IP-10的分离的单克隆抗体，特别是人抗体，抑制IP-10与其受体的结合，抑制IP-10诱导的钙通量并抑制IP-10诱导的细胞迁移 。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体来抑制IP-10活性的方法，包括治疗各种炎性和自身免疫性疾病的方法。
-
7.发明公开Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 审中-公开为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2439272A3
公开(公告)日：2013-07-31
申请号：EP11178188.6
申请日：2006-05-02
发明人： Srinivasan, Mohan , Wang, Changyu , Selby, Mark, J. , Chen, Bing , Cardarelli, Josephine, M. , Korman, Alan, J. , Huang, Haichun
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
8.发明公开Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 审中-公开为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2439273A2
公开(公告)日：2012-04-11
申请号：EP11178191.0
申请日：2006-05-02
发明人： Srinivasan, Mohan , Wang, Changyu , Selby, Mark J. , Chen, Bing , Cardarelli, Josephine M. , Korman, Alan J.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/464 , Y02A50/466 , Y02A50/467 , Y02A50/469 , Y02A50/478 , Y02A50/487 , Y02A50/489
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
摘要翻译： 本发明提供了分离的单克隆抗体，特别是人单克隆抗体，并特异性结合PD-1以高亲和力。 编码本发明的抗体的核酸分子，表达载体，宿主细胞和表达本发明的抗体的方法因此提供。 因此免疫缀合物，双特异性分子和药物组合物包含本发明的抗体提供的。 因此，本发明提供了用于治疗各种疾病，包括癌症和感染性疾病，使用抗PD-1抗体用于检测PD-1的方法，以及方法。 本发明进一步提供了使用免疫疗法组合,:方法如抗CTLA-4和抗PD-1抗体的组合，以治疗过度增殖性疾病，：如癌症。 因此本发明提供用于改变与治疗相关的独立与测试的抗体的不良事件的方法。
-
9.发明公开Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 有权为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2161336A1
公开(公告)日：2010-03-10
申请号：EP09013687.0
申请日：2006-05-02
发明人： Korman, Alan, J. , Srinivasan, Mohan , Wang, Changyu , Selby, Mark. J. , Chen, Bing , Cardarelli, Josephine M.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
10.发明授权Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 有权针对程序性死亡1的人单克隆抗体（PD-1）以及单独或与其他免疫治疗剂组合使用抗PD-1抗体治疗癌症的方法
公开(公告)号：EP2161336B1
公开(公告)日：2013-07-31
申请号：EP09013687.0
申请日：2006-05-02
发明人： Korman, Alan, J. , Srinivasan, Mohan , Wang, Changyu , Selby, Mark. J. , Chen, Bing , Cardarelli, Josephine M. , Huang, Haichun
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.021 秒)
